Quick Answer
Mineralys Therapeutics, Inc. reported Net Income Loss of -$154.65 million for the year ending 2025.
- Mineralys Therapeutics, Inc. showed an increase of +13.0% in Net Income Loss from 2024 to 2025.
- This data is from Mineralys Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), Mineralys Therapeutics, Inc.'s Net Income Loss has declined by 419.0%.
- Historical annual values: Fiscal year 2025: -$154.65 million | Fiscal year 2024: -$177.81 million | Fiscal year 2023: -$71.90 million | Fiscal year 2022: -$29.80 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: